SCHEDULE: BML Investment Partners Reports Zero Athira Pharma Stake

BML Investment Partners, L.P. and Leonard Braden Michael have reported a 0% beneficial ownership in Athira Pharma Inc.'s common stock.

Summary

• BML Investment Partners, L.P. and Leonard Braden Michael filed an Amendment No. 3 to Schedule 13G for Athira Pharma Inc.
• As of the event date, both reporting persons beneficially own 0 shares of Athira Pharma Inc. common stock.
• This represents 0% of the class of securities.
• The reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1) of the Exchange Act.

Sentiment

Score: 5

Explanation: The filing is a routine beneficial ownership disclosure (Schedule 13G Amendment) reporting 0% ownership. It provides no operational or financial information about Athira Pharma Inc., thus having a neutral sentiment score.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Athira Pharma Inc.'s operations or financial performance.

Management Comments

• BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M. Leonard. As a result, Braden M. Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P.
• Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1) of the Exchange Act.
• The securities referred to were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This is a routine disclosure of a change in beneficial ownership by an institutional investor, indicating a reduction in their stake below the reporting threshold or a complete divestment. It does not provide insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Minimal direct impact, as it's a disclosure of a previous investor's exit or reduction below the reporting threshold, not a new investment or activist position.

Key Dates

Keywords

Athira Pharma, BML Investment Partners, Leonard Braden Michael, Schedule 13G, beneficial ownership, common stock, divestment